ADVI’s Lindsay Bealor Greenleaf, vice president and head of policy and reimbursement, sat down with Bloomberg Law to discuss how the new drug pricing bill might shift dollars away from cancer meds. “Under this bill, there is no incentive to research new indications or new formulations of existing drugs. Period. Because you don’t have the opportunity to restart that thirteen-year clock for biologics or nine-year clock for small molecules.” Hear more from Lindsay and other experts on this topic here.